International Pompe Association

You are here: Home News First Patient Infused in Amicus' Co-administration Clinical Study

Amicus Therapeutics announced that the first patient has been infused in the AT2220-010 Phase 2 co-administration clinical study of AT2220 (duvoglustat HCl), the investigational pharmacological chaperone for the treatment of Pompe disease, and enzyme replacement therapy. The press release is attached with more details about this drug-drug interaction study for your reference. Recruitment for the study is ongoing. Additional information about study design and current study site locations can be found at www.pompestudy.com and www.clinicaltrials.gov/ct2/show/NCT01380743?term=AT2220&rank=2.

Link to press release: http://ir.amicustherapeutics.com/releasedetail.cfm?ReleaseID=629205

 


Disclaimer: The IPA does not endorse any of the products, medications, treatments or information reported herein. Articles on the IPA web pages are intended for informational purposes, only. We strongly advise that you discuss all medications, treatments, and/or products with your physician.